TransCode Therapeutics Inc. (NASDAQ: RNAZ) has initiated a Phase 2a clinical trial to evaluate its drug candidate TTX-MC138 in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE